Viveve Medical, Inc. (NASDAQ:VIVE) has received a consensus recommendation of “Buy” from the six analysts that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average 12-month price target among brokerages that have covered the stock in the last year is $10.50.

A number of equities research analysts recently issued reports on the stock. Mizuho began coverage on shares of Viveve Medical in a research note on Thursday. They issued a “buy” rating on the stock. Cowen and Company set a $11.00 target price on shares of Viveve Medical and gave the stock a “buy” rating in a research note on Monday, October 23rd. ValuEngine cut shares of Viveve Medical from a “sell” rating to a “strong sell” rating in a research note on Monday, August 14th. Finally, Maxim Group reaffirmed a “buy” rating and set a $11.00 target price on shares of Viveve Medical in a research note on Friday, August 11th.

In other Viveve Medical news, CFO Scott Durbin bought 5,000 shares of the stock in a transaction on Wednesday, August 23rd. The shares were bought at an average price of $5.25 per share, with a total value of $26,250.00. Following the purchase, the chief financial officer now directly owns 11,568 shares in the company, valued at approximately $60,732. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 35.10% of the company’s stock.

Several hedge funds have recently made changes to their positions in the company. Rhumbline Advisers acquired a new position in shares of Viveve Medical during the 2nd quarter valued at about $110,000. JPMorgan Chase & Co. acquired a new position in shares of Viveve Medical during the 2nd quarter valued at about $151,000. Virtu KCG Holdings LLC acquired a new position in shares of Viveve Medical during the 2nd quarter valued at about $169,000. Granahan Investment Management Inc. MA boosted its position in shares of Viveve Medical by 32.6% during the 3rd quarter. Granahan Investment Management Inc. MA now owns 102,147 shares of the company’s stock valued at $535,000 after acquiring an additional 25,097 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. acquired a new position in shares of Viveve Medical during the 2nd quarter valued at about $189,000. 65.55% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This report was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another publication, it was stolen and republished in violation of US & international copyright laws. The legal version of this report can be read at https://www.thecerbatgem.com/2017/11/16/viveve-medical-inc-vive-receives-consensus-rating-of-buy-from-brokerages.html.

Viveve Medical (NASDAQ VIVE) traded up $0.05 during trading hours on Thursday, hitting $4.81. 129,047 shares of the stock traded hands, compared to its average volume of 186,733. The company has a quick ratio of 3.63, a current ratio of 3.89 and a debt-to-equity ratio of 2.72. Viveve Medical has a 52-week low of $3.75 and a 52-week high of $11.16.

Viveve Medical (NASDAQ:VIVE) last released its quarterly earnings results on Wednesday, November 8th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.08). Viveve Medical had a negative net margin of 257.58% and a negative return on equity of 275.77%. The company had revenue of $4.07 million during the quarter, compared to analyst estimates of $4.10 million. During the same period in the prior year, the business posted ($0.46) EPS. Viveve Medical’s revenue was up 120.1% compared to the same quarter last year. analysts expect that Viveve Medical will post -2 earnings per share for the current fiscal year.

About Viveve Medical

Viveve Medical, Inc designs, develops, manufactures and markets a medical device, Geneveve, for the non-invasive treatment of vaginal laxity, for improved sexual function, and for vaginal rejuvenation. The Company’s, Geneveve, is a non-invasive solution for vaginal laxity, which includes three components: the Viveve System (a radio frequency (RF), generator housed in a table-top console), a reusable handpiece and a single-use treatment tip, as well as several other consumable accessories.

Analyst Recommendations for Viveve Medical (NASDAQ:VIVE)

Receive News & Stock Ratings for Viveve Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical Inc. and related stocks with our FREE daily email newsletter.